Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tarlatamab study in elderly patients with relapsed or progressive small cell lung cancer after platinum chemotherapy
jRCT1061260084Phase 2Recruiting
- Start
- Nov 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in small cell lung cancer (SCLC). Primary endpoint: 1-year progression-free survival rate. Started Nov 2026; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT1061260084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061260084.